Bosutinib 100mg Tablets$101.00
1–9 boxes
$101.00 each
10–24 boxes
8% off
25+ boxes
10% off
Bosutinib 100mg Tablets
SKU GME1364Oncology Care
Product Introduction
Bosutinib 100mg is a BCR–ABL tyrosine-kinase inhibitor for Philadelphia-chromosome-positive chronic myeloid leukaemia. Selection depends on disease phase, prior treatment and the mutation profile.
How to use
Take tablets with food at a consistent daily time and swallow whole. Do not crush or split. Avoid grapefruit. Separate short-acting antacids or H2 blockers by more than 2 hours; proton-pump inhibitors can reduce absorption.
How it works
Bosutinib inhibits BCR–ABL and Src-family kinases, reducing proliferative signalling in susceptible leukaemic cells.
Side effects
Diarrhoea, nausea, abdominal pain, rash, low blood counts and increased liver enzymes can occur. Fluid retention and kidney-function decline are important concerns.
Important information
Monitor blood counts, liver enzymes and kidney function, particularly early in treatment. CYP3A inhibitors and inducers can substantially change exposure. Persistent diarrhoea can cause dehydration.
Uses
- Philadelphia-chromosome-positive chronic myeloid leukaemia in an appropriate treatment setting.
Benefits
Suppressing BCR–ABL signalling can reduce the leukaemic-cell burden and maintain haematological and molecular disease control.
Does a normal white-cell count prove a complete response?
No. Molecular BCR–ABL testing measures residual disease more sensitively than the routine count.
Can omeprazole reduce effectiveness?
Yes. Lower stomach acidity can reduce bosutinib absorption, so the acid-suppression regimen may need changing.
What should I do if I miss a bosutinib dose?
Take the missed dose with food if no more than 12 hours have passed since it was due. If more than 12 hours have passed, skip it and resume the usual schedule. Do not double the dose.
Why report diarrhoea early rather than waiting for the next visit?
Early treatment and fluids can prevent dehydration and reduce the chance of a prolonged interruption.
BCR–ABL: an abnormal fusion kinase driving most CML. Philadelphia chromosome: a chromosome change producing BCR–ABL. Molecular response: reduction in measurable leukaemia-related genetic material.; AR: Bosutinib 100mg أقراص; FR: Bosutinib 100mg comprimés; PT: Bosutinib 100mg comprimidos; ES: Bosutinib 100mg comprimidos; RU: Bosutinib 100mg таблетки; ID: Bosutinib 100mg tablet; VI: Bosutinib 100mg viên nén; MS: Bosutinib 100mg tablet; TL: Bosutinib 100mg mga tableta; ZH-SG: Bosutinib 100mg 片剂